Susquehanna International Group’s Neumora Therapeutics NMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$311K Buy
159,500
+98,400
+161% +$255K ﹤0.01% 10784
2025
Q4
$109K Buy
61,100
+24,600
+67% +$53.9K ﹤0.01% 11406
2025
Q3
$66.4K Buy
36,500
+24,200
+197% +$39.1K ﹤0.01% 11763
2025
Q2
$8.98K Sell
12,300
-15,500
-56% -$11.7K ﹤0.01% 12410
2025
Q1
$27.8K Sell
27,800
-410,000
-94% -$702K ﹤0.01% 12032
2024
Q4
$4.64M Buy
437,800
+400,900
+1,086% +$4.8M ﹤0.01% 3713
2024
Q3
$487K Buy
+36,900
New +$430K ﹤0.01% 8524
2024
Q1
Sell
-14,200
Closed -$242K 12952
2023
Q4
$242K Buy
+14,200
New +$174K ﹤0.01% 10292

Other funds holding NMRA

Susquehanna International Group's NMRA Position: Q1 2026 in Review

Susquehanna International Group increased its Neumora Therapeutics (NMRA) stake by 68% in Q1 2026, buying an estimated $1.3M and bringing the position to 1,240,241 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #5738.

Susquehanna International Group first reported a position in NMRA in Q3 2023 and has held it in 11 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Susquehanna International Group held 1,240,241 shares of Neumora Therapeutics worth $2.42M as of Q1 2026.
  • Susquehanna International Group bought 501,969 Neumora Therapeutics shares in Q1 2026, an estimated $1.3M.
  • Neumora Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5738 holding.
  • Susquehanna International Group first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.